Business Context and Reporting Period
Company: Allogene Therapeutics, Inc. (ALLO)
Filing Type: Form 8-K (Current Report)
Date of Report: September 26, 2025 (Event Date); October 10, 2025 (Signature Date)
Context: The filing discloses a material legal event involving a third-party patent infringement lawsuit against the company's technology licensor, Cellectis S.A.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is strictly a disclosure of a legal event.
Material Changes and Events
- Patent Litigation: On September 26, 2025, Factor Bioscience Inc. filed a complaint in the U.S. District Court for the District of Delaware against Cellectis S.A. and Cellectis, Inc.
- Allegations: Factor alleges Cellectis infringed three of its U.S. patents regarding TALEN-based gene-editing technology. Factor claims Cellectis copied Factor's patented mRNA TALEN technology and licensed it to third parties, including Allogene.
- Additional Defendants: AstraZeneca PLC and affiliates are named as defendants for alleged direct infringement by using Cellectis's technology.
- Company Reliance: Allogene relies on the TALEN technology licensed from Cellectis to engineer specific allogeneic CAR T cell product candidates, including cema-cel and ALLO-316.
- Current Status: Cellectis notified Allogene on October 6, 2025, stating it disputes the claims and intends to vigorously defend them. Allogene is not currently a named party but faces potential future direct claims.
Guidance, Outlook, and Risks
Management Commentary: The filing references risk factors previously disclosed in the Form 10-Q for the quarter ended June 30, 2025. These include risks related to the novelty of gene-editing technology, heavy reliance on partners (Cellectis and Servier) for TALEN access, and the potential for third-party IP claims to delay or prevent commercialization.
Contingencies: Factor Bioscience may assert direct claims against Allogene as a commercial user of the disputed technology. The outcome of this litigation could materially limit revenue opportunities if Allogene is unable to continue using the licensed technology.
Investor Verification Checklist
- Verify the specific scope of the patent claims against the TALEN technology used in cema-cel and ALLO-316.
- Monitor for any subsequent filings indicating if Factor Bioscience adds Allogene as a direct defendant.
- Review the Form 10-Q (filed August 13, 2025) for detailed risk factor disclosures regarding IP dependencies.
- Assess the potential impact on the development timeline and commercialization strategy if the license with Cellectis is invalidated or restricted.